Key Milestones

Historical Timeline of Serum Institute's Achievements

01

1966
Founded by Dr. Cyrus Poonawalla
 Key Milestones
Historical Timeline of Serum Institute's Achievements

01
Introduced the MMR vaccine
1989

1966
Founded by Dr. Cyrus Poonawalla
02
 Key Milestones
Historical Timeline of Serum Institute's Achievements

01 03
Introduced the MMR vaccine
1989

1966 2007
Founded by Dr. Cyrus Poonawalla Developed the rotavirus vaccine
02
 Key Milestones
Historical Timeline of Serum Institute's Achievements

01 03 •Collaboration with AstraZeneca for

Introduced the MMR vaccine COVID-19 vaccine (Covishield)
1989 2020

1966 2007
Founded by Dr. Cyrus Poonawalla Developed the rotavirus vaccine
02 02
Serum Institute of
India
CEO and Founder of Serum Institute of India

Dr. Cyrus S. Poonawalla Adar Poonawalla

Serum Institute of
India
CEO and Founder of Serum Institute of India

1.Company Overview:
1. Founded in 1966 by Cyrus Poonawalla in Pune, India.
2. Initially focused on producing immunobiological to counter imported high-priced vaccines.
2.Product Range and Expansion:
1. Initially produced tetanus antitoxin, snake antivenom, DPT vaccine, and MMR vaccine.
2. Expanded product lines to include vaccines against various infections, combination vaccines,
influenza vaccine, and meningococcal vaccine.
3. Also manufactures antisera, blood plasma, and hormone products.
3.Global Impact:
1. Products used in international vaccination programs by WHO, UNICEF, and PAHO.
2. Known for Tubervac (BCG), Poliovac for poliomyelitis, and other childhood vaccinations.
4.Major Achievements:
1. Developed intranasal swine flu vaccine in 2009.
2. Acquired Bilthoven Biologicals in the Netherlands in 2012.
3. Invented Rabies Human Monoclonal Antibody (RMAb) in 2016.
4. Largest vaccine producer globally as of 2023, with plans to produce 4 billion doses yearly.
5.COVID-19 Vaccine Development:
1. Partnered with AstraZeneca to produce AZD1222 (Covishield) vaccine.
2. Targeted to supply 1 billion doses by the end of 2021.
3. Additional agreements with Novavax and Codagenix for vaccine production.
4. Collaboration with Gamaleya Research Institute for Sputnik V vaccine production.
Serum Institute of
India
CEO and Founder of Serum Institute of India

Dr. Cyrus S. Poonawalla Adar Poonawalla

 Serum Institute of
India
CEO and Founder of Serum Institute of India

• Cyrus S. Poonawalla (born • Poonawalla Fincorp a leading

in 1941) is an Indian NBFC in India.[1][2]
billionaire businessman, and
• In 2022, he is ranked as the 4th
the chairman and managing
director of the Cyrus richest person in India on
Poonawalla Group Forbes India rich list with a net
worth of $24.3 billion.[3]
• Includes the Serum Institute
• He is ranked number 1 on the
of India, an Indian biotech
company which is the largest Hurun Global Healthcare Rich
vaccine manufacturer in the List 2022.
world

Dr. Cyrus S. Poonawalla

Serum Institute of
India
CEO and Founder of Serum Institute of India

Dr. Cyrus S. Poonawalla Adar Poonawalla

 Serum Institute of
India
CEO and Founder of Serum Institute of India

• Adar Poonawalla is the CEO of Serum Institute of India (SII), one of the world's
largest vaccine manufacturers.

• CEO of Serum Institute of India (SII): Adar Poonawalla took over as CEO of SII, the world's
largest vaccine manufacturer by volume, from his father, Cyrus Poonawalla. Under his
leadership, SII has grown exponentially, producing millions of doses of vaccines annually.

• Vaccine Production: Poonawalla has overseen the production of a wide range of vaccines,
including those for diseases like measles, mumps, rubella, polio, influenza, and more
recently, COVID-19. SII's role in producing the Oxford-AstraZeneca COVID-19 vaccine,
known as Covishield in India, has been instrumental in the global fight against the
pandemic.

• Global Reach: Through strategic partnerships and collaborations, Poonawalla has expanded
SII's reach globally, supplying vaccines to over 170 countries. This has positioned SII as a
key player in the global vaccine market.

• Recognitions and Awards: Poonawalla's contributions to the field of healthcare and vaccine
production have earned him recognition and accolades, including being named among the
most influential people in the world by Time magazine. Adar Poonawalla
Leading the Growth of Serum Institute of India
Founding Vision
Dr. Cyrus S. Poonawalla's vision led to the establishment
of Serum Institute of India, focusing on providing
effective vaccine solutions to global healthcare challenges.
Leading the Growth of Serum Institute of India
Founding Vision
Dr. Cyrus S. Poonawalla's vision led to the establishment
of Serum Institute of India, focusing on providing
effective vaccine solutions to global healthcare challenges.

Strategic Leadership
Under the leadership of Dr. Cyrus S.
Poonawalla, Serum Institute of India has
achieved remarkable growth, driven by
strategic decision-making and innovative
approaches.
Leading the Growth of Serum Institute of India
Founding Vision
Dr. Cyrus S. Poonawalla's vision led to the establishment
of Serum Institute of India, focusing on providing
effective vaccine solutions to global healthcare challenges.

Strategic Leadership
Under the leadership of Dr. Cyrus S.
Poonawalla, Serum Institute of India has
achieved remarkable growth, driven by
strategic decision-making and innovative
approaches.

Overcoming Challenges
Dr. Cyrus S. Poonawalla navigated through initial
struggles, transforming Serum Institute of India into
a leading vaccine manufacturer through resilience
and perseverance.
 Leading the Growth of Serum Institute of India
Founding Vision
Dr. Cyrus S. Poonawalla's vision led to the establishment
of Serum Institute of India, focusing on providing
effective vaccine solutions to global healthcare challenges.

Strategic Leadership
Under the leadership of Dr. Cyrus S.
Poonawalla, Serum Institute of India has
achieved remarkable growth, driven by
strategic decision-making and innovative
approaches.

Adar C. Poonawalla's
Leadership Overcoming Challenges
As the CEO, Mr. Adar C. Poonawalla has played a Dr. Cyrus S. Poonawalla navigated through initial
pivotal role in the company's growth, expanding its struggles, transforming Serum Institute of India into
global footprint and driving innovation in vaccine a leading vaccine manufacturer through resilience
production. and perseverance.
 Leading the Growth of Serum Institute of India
Founding Vision
Dr. Cyrus S. Poonawalla's vision led to the establishment
of Serum Institute of India, focusing on providing
Global Impact effective vaccine solutions to global healthcare challenges.
Under the leadership of Dr. Cyrus S. Poonawalla and
Mr. Adar C. Poonawalla, Serum Institute of India has
emerged as a key player in global vaccine
production, addressing critical healthcare needs
worldwide.

Strategic Leadership
Under the leadership of Dr. Cyrus S.
Poonawalla, Serum Institute of India has
achieved remarkable growth, driven by
strategic decision-making and innovative
approaches.

Adar C. Poonawalla's
Leadership Overcoming Challenges
As the CEO, Mr. Adar C. Poonawalla has played a Dr. Cyrus S. Poonawalla navigated through initial
pivotal role in the company's growth, expanding its struggles, transforming Serum Institute of India into
global footprint and driving innovation in vaccine a leading vaccine manufacturer through resilience
production. and perseverance.
Dr. Cyrus S.
Poonawalla - CEO
and Founder

Navigating Challenges and Driving

Growth
 Early Struggles
Overcame initial financial constraints to establish the
Serum Institute of India.

Dr. Cyrus S.
Poonawalla - CEO
and Founder

Navigating Challenges and Driving

Growth
 Early Struggles
Overcame initial financial constraints to establish the
Serum Institute of India.

Global Expansion
Dr. Cyrus S. •Led the company to become the world's largest
vaccine manufacturer by doses.

Poonawalla - CEO
and Founder

Navigating Challenges and Driving

Growth
 Early Struggles
Overcame initial financial constraints to establish the
Serum Institute of India.

Global Expansion
Dr. Cyrus S. •Led the company to become the world's largest
vaccine manufacturer by doses.

Poonawalla - CEO
Social Impact
and Founder •Contributed significantly to global immunization
efforts, positively impacting public health.

Navigating Challenges and Driving

Growth
 Early Struggles
Overcame initial financial constraints to establish the
Serum Institute of India.

Global Expansion
Dr. Cyrus S. •Led the company to become the world's largest
vaccine manufacturer by doses.

Poonawalla - CEO
Social Impact
and Founder •Contributed significantly to global immunization
efforts, positively impacting public health.

Navigating Challenges and Driving Financial Milestones

Growth Achieved remarkable revenue and profit growth over
the years.
 SWOT Analysis for Serum Institute of India
Assessment of Internal Strengths and Weaknesses, and External Opportunities and Threats
 SWOT Analysis for Serum Institute of India
Assessment of Internal Strengths and Weaknesses, and External Opportunities and Threats
 Covaxin VS. Covishield

1. Type of Vaccine
2. Manufactures
3. Technology
4. Dosage schedule
5. Efficiency
6. Storage Condition
7. Approval Status
8. Clinical Trials
9. Global Distribution
10. Price
 1. 2. 3. 4. 5.

Healthcare Community Employee

access Development Welfare

Educational
and Skill Disaster relief
Development
 Corporate Social
1. 2. Responsibility(CSR)
3. 4. 5.

Healthcare Community Employee

access Development Welfare

Educational
and Skill Disaster relief
Development
Why serum
institute of
india's vaccines
are cheaper
than others??
1.Economies of Scale: SII is the world's largest vaccine manufacturer by volume. This allows them to benefit from economies of
scale, which reduces the cost per unit of vaccine produced.

2.Government Support: SII receives support from the Indian government, which helps in keeping production costs low. This
support can come in the form of subsidies, tax incentives, or other financial assistance.

3.Low Labor Costs: Labor costs in India are generally lower compared to many other countries. This contributes to lower overall
production costs for SII.

4.Efficient Supply Chain: SII has developed an efficient supply chain that helps in reducing costs associated with transportation
and storage of vaccines.

5.Access to Technology: SII has access to technology for vaccine production and has developed expertise in this area over the
years, enabling them to produce vaccines more efficiently.

6.Licensing and Partnerships: SII has entered into licensing agreements and partnerships with other vaccine manufacturers,
allowing them to produce vaccines at a lower cost.

7.Philanthropic Efforts: SII has a strong commitment to making vaccines affordable and accessible, which is reflected in their
pricing strategy.